0001817048-21-000001.txt : 20210506 0001817048-21-000001.hdr.sgml : 20210506 20210506130321 ACCESSION NUMBER: 0001817048-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 EFFECTIVENESS DATE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gilgamesh Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001817048 IRS NUMBER: 842552195 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-398477 FILM NUMBER: 21896862 BUSINESS ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 BUSINESS PHONE: 347-967-6831 MAIL ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 D 1 primary_doc.xml X0708 D LIVE 0001817048 Gilgamesh Pharmaceuticals, Inc. 113 University Place Suite 1019 New York NY NEW YORK 10003 3479676831 DELAWARE None None Corporation true 2019 Jonathan Sporn 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Andrew Kruegel 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Robert Berman 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Dalibor Sames 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Sames resigned as a Director, effective upon closing of the transaction. Amy Kruse P.O. Box 12829 Jackson WY WYOMING 83002 Director Kruse was appointed as a Director, effective upon closing of the transaction. Pharmaceuticals Decline to Disclose 06b false 2021-04-26 false true true In addition to the shares of preferred stock sold by the Issuer, the shares of Issuer capital stock into which such shares of preferred stock may convert. false 10000 34701891 34701837 54 false 66 0 0 630000 true Some of the proceeds will be used to pay the salary of executive officers of the Issuer. false Gilgamesh Pharmaceuticals, Inc. John Fallone /s/ John Fallone Attorney for Issuer 2021-05-06